{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:10:46Z","timestamp":1787019046907,"version":"build-2736575974"},"reference-count":18,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T00:00:00Z","timestamp":1757808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Aztreonam-avibactam (ATM-AVI) is used for difficult-to-treat gram-negative infections. The objective of this review is to analyze the pharmacology, safety, and clinical application of ATM-AVI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>PubMed, Embase, and ClinicalTrials.gov were searched using the terms aztreonam avibactam, PF-06947387, Emblaveo, and ATM-AVI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>Articles written in English and published from January 1, 1985, to June 10, 2025, that related to pharmacology, safety, clinical trials, and clinical application of ATM-AVI were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>The ATM-AVI has shown similar efficacy to comparator antibiotics in complicated intra-abdominal infection (cIAI) and hospital\/ventilator-acquired pneumonia (HAP\/VAP). The REVISIT trial showed cIAI clinical cure rates of 76.4% and 74% for the ATM-AVI and meropenem groups, respectively (treatment difference 2.4% [95% confidence interval, CI = \u22127.4 to 13.0]). For HAP\/VAP, clinical cure rates were 45.9% and 41.7% for the ATM-AVI and meropenem groups, respectively (treatment difference 4.3% [95% CI = \u221215.1 to 23.1]). The ATM-AVI was generally well tolerated, with hepatic adverse effects being the most commonly reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice comparison to existing drugs:<\/jats:title>\n                    <jats:p>The ATM-AVI has demonstrated clinical efficacy for the treatment of cIAI. However, its role needs to be further studied for other infections such as HAP\/VAP, urinary tract, and other serious infections. Pharmacoeconomic analysis may be needed to assess the cost-benefit impact in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The ATM-AVI may be an alternative option for the treatment of cIAI and other complicated gram-negative infections. Further studies are needed to delineate the role of ATM-AVI in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251366033","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T02:35:27Z","timestamp":1757903727000},"page":"296-302","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Combination of Aztreonam-Avibactam in Multidrug-Resistant Gram-Negative Infections"],"prefix":"10.1177","volume":"60","author":[{"given":"Maria","family":"Roye-Azar","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Prater","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0540-785X","authenticated-orcid":false,"given":"Christopher","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"},{"name":"Henry Ford St. John Hospital, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini B.","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Detroit, MI, USA"},{"name":"Henry Ford St. John Hospital, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,14]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"CDC. Antimicrobial resistance threats in the United States 2021-2022. Antimicrobial resistance. Published February 4 2025. Accessed March 14 2025. https:\/\/www.cdc.gov\/antimicrobial-resistance\/data-research\/threats\/update-2022.html"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9040186"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S246174"},{"key":"e_1_3_2_5_2","unstructured":"AbbVie News Center. U.S. FDA approves EMBLAVEOTM (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections with limited or no treatment options. Accessed March 14 2025. https:\/\/news.abbvie.com\/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options"},{"key":"e_1_3_2_6_2","unstructured":"Emblaveo (aztreonam and avibactam) [package insert]. AbbVie Inc. Accessed February 10 2025. https:\/\/www.rxabbvie.com\/pdf\/emblaveo_pi.pdf"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw231"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.03057-14"},{"key":"e_1_3_2_9_2","unstructured":"Pfizer. A Phase I Single Center Open-Label Study to Assess the Pharmacokinetics Safety and Tolerability of Aztreonam-Avibactam Administered as Single and Repeated Intravenous Doses in Healthy Chinese Participants. ClinicalTrials.gov; 2022. Accessed May 15 2025. https:\/\/clinicaltrials.gov\/study\/NCT04973826"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00936-22"},{"key":"e_1_3_2_11_2","unstructured":"van den Berg F. A Phase I Randomised Double-Blind 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI). ClinicalTrials.gov; 2017. Accessed May 15 2025. https:\/\/clinicaltrials.gov\/study\/NCT01689207"},{"key":"e_1_3_2_12_2","unstructured":"Pfizer. An Open-Label Parallel-Group Pharmacokinetic Study of Multiple Intravenous Doses of Aztreonam and Avibactam in Subjects With Severe Renal Impairment and Normal Renal Function. ClinicalTrials.gov; 2022. Accessed May 15 2025. https:\/\/clinicaltrials.gov\/study\/NCT04486625"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz497"},{"key":"e_1_3_2_14_2","unstructured":"European Medicines Agency. Emblaveo. Published 2024. Accessed June 5 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emblaveo-epar-product-information_en.pdf"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00499-7"},{"key":"e_1_3_2_16_2","unstructured":"Pfizer. A Phase 2A 2-Part Open-Label Non-Randomized Multicenter Single and Multiple Dose Trial to Evaluate Pharmacokinetics Safety and Tolerability of Aztreonam and Avibactam \u00b1 Metronidazole in Neonates and Infants From Birth to Less Than 9 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment. ClinicalTrials.gov; 2025. Accessed June 1 2025. https:\/\/clinicaltrials.gov\/study\/NCT06462235"},{"key":"e_1_3_2_17_2","unstructured":"Pfizer. A Phase 2A Multicenter Observer-Blinded Randomized 2 Arm Study to Investigate Pharmacokinetics Safety Tolerability and Efficacy of Intravenous Aztreonam-Avibactam \u00b1 Metronidazole Compared to Best Available Therapy (Bat) in Pediatric Participants 9 Months to Less Than 18 Years of Age With Serious Gram-Negative Bacterial Infections Including Complicated Intra-Abdominal Infection. ClinicalTrials.gov; 2025. Accessed June 1 2025. https:\/\/clinicaltrials.gov\/study\/NCT05639647"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.307"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251366033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251366033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251366033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:15Z","timestamp":1777374855000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251366033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,14]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1177\/10600280251366033"],"URL":"https:\/\/doi.org\/10.1177\/10600280251366033","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,14]]}}}